Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma

Br J Haematol. 2013 Jul;162(1):138-41. doi: 10.1111/bjh.12326. Epub 2013 Apr 17.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cyclophosphamide / adverse effects
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / adverse effects
  • Doxorubicin / therapeutic use
  • Humans
  • Hydroxamic Acids / administration & dosage*
  • Lymphoma, T-Cell, Peripheral / drug therapy*
  • Prednisone / adverse effects
  • Prednisone / therapeutic use
  • Treatment Outcome
  • Vincristine / adverse effects
  • Vincristine / therapeutic use
  • Vorinostat

Substances

  • Hydroxamic Acids
  • Vorinostat
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol